AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7386234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28777385 — intervention group
Group type: EXPERIMENTAL
Intervention: XLHA + CoQ10
Number of subjects: 40
Study 28777385 — intervention group
Group type: COMPARATOR
Intervention: HA
Number of subjects: 40
Study 26701971 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose methotrexate (n = 46)
Number of subjects: 92
Study 26701971 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose methotrexate (n = 46)
Number of subjects: 92
Study 24134194 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-020 (n=52)
Number of subjects: 105
Study 24134194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=53)
Number of subjects: 105
Study 24134194 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-020
Number of subjects: 105
Study 23952894 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 37
Study 23952894 — intervention group
Group type: COMPARATOR
Intervention: Assessment Only (AO)
Number of subjects: 37
Study 20138809 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 Gy in 13 fractions over 5 weeks
Number of subjects: 2208
Study 20138809 — intervention group
Group type: EXPERIMENTAL
Intervention: 41.6 Gy in 13 fractions over 5 weeks
Number of subjects: 2208
Study 20138809 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy in 15 fractions over 3 weeks
Number of subjects: 2208
Study 20138809 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy in 25 fractions (control)
Number of subjects: 2208
Study 18721224 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) in patients aged 70 and older
Number of subjects: 1813
Study 18721224 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD) in younger cohorts (aged 55 to 69 and 18 to 54)
Number of subjects: 1813
Study 18721224 — intervention group
Group type: EXPERIMENTAL
Intervention: All age groups undergoing HD
Number of subjects: 1813
Study 16629864 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid meal (250 kcal) containing 13C-octanoate, n = 40
Number of subjects: 80
Study 16629864 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal (315 kcal) with 13C-acetate, n = 40
Number of subjects: 80
Study 16629864 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group, n = 40
Number of subjects: 80
Study 16629864 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor handicaps (rigour and action tremor)
Number of subjects: 80
Study 16629864 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of motor impairment (UPDRS)
Number of subjects: 80
Study 14563972 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-279,276 (dose range, 10 to 120 mg)
Number of subjects: 966
Study 14563972 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-279,276 in tissue plasminogen activator-treated subset
Number of subjects: 966
Study 14563972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 966
Study 10573670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ab-Flex
Number of subjects: 26
Study 10573670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ab-Roller
Number of subjects: 26
Study 10573670 — intervention group
Group type: COMPARATOR
Intervention: Standard Crunch
Number of subjects: 26
Study 8546341 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day)
Number of subjects: 21
Study 8546341 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/day)
Number of subjects: 21
Study 8546341 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg/day)
Number of subjects: 21
Study 8546341 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/day) plus Quinapril (10 mg/day)
Number of subjects: 21
Study 8546341 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 21
Study 2035513 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 0
Study 2035513 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression from normal glucose tolerance to impaired glucose tolerance
Number of subjects: 0
Study 2035513 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression from normal glucose tolerance to non-insulin-dependent diabetes
Number of subjects: 0
Study 2035513 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression from impaired glucose tolerance to non-insulin-dependent diabetes
Number of subjects: 0
Study 2035513 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall age-standardized incidence of non-insulin-dependent diabetes
Number of subjects: 0
Study 6762829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre and postoperative gentamycin plus clindamycin or lincomycin
Number of subjects: 88
Study 6762829 — intervention group
Group type: COMPARATOR
Intervention: Postoperative gentamycin plus clindamycin or lincomycin
Number of subjects: 88
Study 3909759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine slow-release tablets, 20 mg twice daily
Number of subjects: 10
Study 3909759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30801500 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with SPD
Number of subjects: 150
Study 30801500 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with SPD (boys)
Number of subjects: 150
Study 30801500 — intervention group
Group type: COMPARATOR
Intervention: Children with TD
Number of subjects: 150
Study 29385062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1000 mg capsules containing 180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid, n = 20)
Number of subjects: 40
Study 29385062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study 26541738 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.3 mcg/kg/h for 24 hours)
Number of subjects: 60
Study 26541738 — intervention group
Group type: COMPARATOR
Intervention: Morphine infusion (3 mg/h for 24 hours)
Number of subjects: 60
Study 24797222 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 154
Study 24797222 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions
Number of subjects: 154
Study 23198510 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate-impregnated wipes used thrice weekly
Number of subjects: 0
Study 23198510 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate-impregnated wipes
Number of subjects: 0
Study 20184866 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate therapy
Number of subjects: 601
Study 20184866 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 601
Study 20184866 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 601
Study 18577886 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg mosapride citrate
Number of subjects: 613
Study 18577886 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg itopride hydrochloride
Number of subjects: 613
Study 18577886 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (100 ml water) alone
Number of subjects: 613
Study 15691343 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (CHX; Chlorhexamed forte, 0.2%)
Number of subjects: 7
Study 15691343 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (Meridol, 250 ppm; ASF)
Number of subjects: 7
Study 15691343 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 7
Study 12492904 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total (0.3% triclosan + 2% pvm/ma)
Number of subjects: 19
Study 12492904 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal Global (0.3% triclosan + 0.75% Zn)
Number of subjects: 19
Study 12492904 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Complete (0.3% triclosan + 5% PPi)
Number of subjects: 19
Study 12492904 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dentifrice (0.3% triclosan + 2% pvm/ma + 0.75% Zn + 4% PPi)
Number of subjects: 19
Study 12492904 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (without anti‐plaque agents)
Number of subjects: 19
Study 10048684 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A supplements (400,000 IU); given at baseline, 4 months, and 8 months after discharge.
Number of subjects: 687
Study 8579884 — intervention group
Group type: EXPERIMENTAL
Intervention: Webril patch
Number of subjects: 6
Study 8579884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hill Top patch
Number of subjects: 6
Study 8579884 — intervention group
Group type: EXPERIMENTAL
Intervention: Finn chamber
Number of subjects: 6
Study 8579884 — intervention group
Group type: EXPERIMENTAL
Intervention: Van der Bend chamber
Number of subjects: 6
Study 2405789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (5 mg/kg/day) for 12 months
Number of subjects: 53
Study 2405789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 2405789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 53
Study 6767959 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin once daily (120 mg)
Number of subjects: 165
Study 6767959 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin twice daily (40/80 mg)
Number of subjects: 165
Study 6767959 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin three times daily (40 mg)
Number of subjects: 165
Study 30467342 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone or hydrocortisone
Number of subjects: 0
Study 30646395 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD + CVD
Number of subjects: 13885
Study 30646395 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD + CAD
Number of subjects: 13885
Study 30646395 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD + CAD + CVD
Number of subjects: 13885
Study 26831124 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril-lercanidipine (EL)
Number of subjects: 36
Study 26831124 — intervention group
Group type: COMPARATOR
Intervention: enalapril-felodipine (EF)
Number of subjects: 36
Study 26831124 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril-lercanidipine (EL) uptitrated to 20 mg/d
Number of subjects: 36
Study 26831124 — intervention group
Group type: COMPARATOR
Intervention: enalapril-felodipine (EF) uptitrated to 10 mg/d
Number of subjects: 36
Study 24559212 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex small group educational seminar on antibiotic prescribing
Number of subjects: 0
Study 24559212 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 0
Study 24559212 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of adult patients affected by odontogenic infections
Number of subjects: 0
Study 22251408 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (mean initiation dose: 23 ± 7 μg/week)
Number of subjects: 40
Study 19556926 — intervention group
Group type: COMPARATOR
Intervention: Oral Contraceptives (OC)
Number of subjects: 571
Study 19556926 — intervention group
Group type: COMPARATOR
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 571
Study 17236845 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) mechanical bowel preparation
Number of subjects: 670
Study 17236845 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate (SP) mechanical bowel preparation
Number of subjects: 670
Study 17236845 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate (SP) with ertapenem antibiotic prophylaxis
Number of subjects: 670
Study 17236845 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) with cefotetan antibiotic prophylaxis
Number of subjects: 670
Study 15059701 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir therapy (900 mg daily)
Number of subjects: 5
Study 15059701 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of valganciclovir therapy
Number of subjects: 5
Study 15059701 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir therapy
Number of subjects: 5
Study 10689236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ETEC B-subunit-inactivated whole cell vaccine
Number of subjects: 0
Study 10689236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9342768 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg hypericum extract (LI 160)
Number of subjects: 13
Study 9342768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg hypericum extract (LI 160)
Number of subjects: 13
Study 9342768 — intervention group
Group type: EXPERIMENTAL
Intervention: 3600 mg hypericum extract (LI 160)
Number of subjects: 13
Study 9342768 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg hypericum extract t.i.d. (5.6 mg total hypericin daily)
Number of subjects: 13
Study 9342768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8396394 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐MV photons
Number of subjects: 126
Study 8396394 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐MV photons
Number of subjects: 126
Study 8396394 — intervention group
Group type: COMPARATOR
Intervention: 4‐MV or 10‐MV photons
Number of subjects: 126
Study 3731706 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (Omnipaque)
Number of subjects: 57
Study 3731706 — intervention group
Group type: COMPARATOR
Intervention: sodium/meglumine diatrizoate (Urografin)
Number of subjects: 57
Study 31713267 — intervention group
Group type: EXPERIMENTAL
Intervention: OPA-15406 0.3%
Number of subjects: 73
Study 31713267 — intervention group
Group type: EXPERIMENTAL
Intervention: OPA-15406 1%
Number of subjects: 73
Study 31713267 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 73
Study 31713267 — intervention group
Group type: EXPERIMENTAL
Intervention: OPA-15406 0.3% and 1%
Number of subjects: 73
Study 30753178 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior decompression
Number of subjects: 80
Study 30753178 — intervention group
Group type: COMPARATOR
Intervention: Posterior decompression
Number of subjects: 80
Study 28230596 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with lyophilized bovine bone granules and pericardium membrane covering
Number of subjects: 20
Study 28230596 — intervention group
Group type: COMPARATOR
Intervention: Control group (empty extraction socket left untreated)
Number of subjects: 20
Study 28230596 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group I and II
Number of subjects: 20
Study 28230596 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (immediate implants)
Number of subjects: 20
Study 26298689 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal Fun program
Number of subjects: 511
Study 26298689 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 511
Study 23452466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet from meat (14 en%)
Number of subjects: 47
Study 23452466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet from grain (14 en%)
Number of subjects: 47
Study 23452466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet from dairy (14 en%)
Number of subjects: 47
Study 21845472 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 10 mg once daily
Number of subjects: 131
Study 21845472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 131
Study 21845472 — intervention group
Group type: COMPARATOR
Intervention: Control group (watchful waiting)
Number of subjects: 131
Study 18482350 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren 3 x 50 mg)
Number of subjects: 29
Study 18482350 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint therapy
Number of subjects: 29
Study 18482350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Diclofenac and Occlusal splint therapy)
Number of subjects: 29
Study 18482350 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 29
Study 18482350 — intervention group
Group type: COMPARATOR
Intervention: Contralateral, symptom-free TMJ
Number of subjects: 29
Study 16847036 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 112
Study 16847036 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study 12766922 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (The Eight Section Brocades) for 12 weeks
Number of subjects: 50
Study 12766922 — intervention group
Group type: COMPARATOR
Intervention: Traditional remedial rehabilitation activities
Number of subjects: 50
Study 10834776 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of isobaric bupivacaine with 25 microg fentanyl
Number of subjects: 32
Study 10834776 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of isobaric (plain) bupivacaine 0.5%
Number of subjects: 32
Study 9489085 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (0.5 or 1 mg once daily, up to 12 mg once daily)
Number of subjects: 609
Study 9489085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 8161441 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment (exact dosage and duration not specified)
Number of subjects: 4
Study 3526984 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (infusion rates between 100 and 300 micrograms X kg‐1 X min‐1)
Number of subjects: 37
Study 3526984 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (200 micrograms X kg‐1 X min‐1)
Number of subjects: 37
Study 3526984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30770767 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week yoga program (n=22)
Number of subjects: 44
Study 30770767 — intervention group
Group type: COMPARATOR
Intervention: Standardized educational film program (n=22)
Number of subjects: 44
Study 30070386 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient psychotherapy (median: 45 sessions)
Number of subjects: 64
Study 30070386 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment (average duration: 9 weeks)
Number of subjects: 64
Study 29104805 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent self-weighing
Number of subjects: 36
Study 25648589 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help Internet intervention 'mastery over dementia' (MoD)
Number of subjects: 149
Study 24121610 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgluteal space technique (30 mL admixture of 1:2 lidocaine 2% and bupivacaine 0.5% with 1:200,000 epinephrine)
Number of subjects: 27
Study 24121610 — intervention group
Group type: COMPARATOR
Intervention: Infragluteal technique (30 mL admixture of 1:2 lidocaine 2% and bupivacaine 0.5% with 1:200,000 epinephrine)
Number of subjects: 27
Study 20858088 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio frequency regional hyperthermia combined with gemcitabine and cisplatin (GP)
Number of subjects: 80
Study 20858088 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin (GP) alone
Number of subjects: 80
Study 17951021 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment (SC) as an adjunct to substance abuse treatment-as-usual (TAU)
Number of subjects: 225
Study 17951021 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment (SC)
Number of subjects: 225
Study 17951021 — intervention group
Group type: COMPARATOR
Intervention: Substance abuse treatment-as-usual (TAU)
Number of subjects: 225
Study 16971616 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix detachable coils
Number of subjects: 236
Study 14983955 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prostate-specific antigen (PSA) determination, digital rectal examination (DRE), transrectal ultrasonography (TRUS) as screening tests
Number of subjects: 42376
Study 14983955 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PSA level > or = 3.0 ng/mL as an indication for sextant biopsy
Number of subjects: 42376
Study 10737317 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary unilateral pharyngeal myotomy
Number of subjects: 60
Study 10737317 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurectomy of the pharyngeal plexus in addition to pharyngeal myotomy
Number of subjects: 60
Study 10737317 — intervention group
Group type: COMPARATOR
Intervention: No additional surgical procedure
Number of subjects: 60
Study 7986334 — intervention group
Group type: EXPERIMENTAL
Intervention: Live VZV vaccine (4,000 PFU of Oka strain)
Number of subjects: 0
Study 7986334 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated VZV vaccine (similar amount to live vaccine)
Number of subjects: 0
Study 7986334 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) immunization (3 months before VZV vaccine)
Number of subjects: 0
Study 3151688 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 3x80 mg and Gentamycin 3x80 mg
Number of subjects: 54
Study 3151688 — intervention group
Group type: COMPARATOR
Intervention: Metronidazol 3x500 mg and Gentamycin 3x80 mg
Number of subjects: 54
Study 30466348 — intervention group
Group type: EXPERIMENTAL
Intervention: Theater-based intervention including a play, value exercises, chlamydia games, condom school, and interactive replay with professional actors and staff from a youth guidance center.
Number of subjects: 0
Study 30466348 — intervention group
Group type: COMPARATOR
Intervention: Standard sex education from school staff (Control group).
Number of subjects: 0
Study 31204204 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame rehabilitation using Motion Rehab AVE 3D
Number of subjects: 31
Study 31204204 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 31
Study 28196533 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified cereal (Cer)
Number of subjects: 87
Study 28196533 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified cereal with fruit (Cer + Fr)
Number of subjects: 87
Study 28196533 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat (M)
Number of subjects: 87
Study 28196533 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Cer, Cer + Fr, M)
Number of subjects: 87
Study 28196533 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat (M) or Iron-fortified cereal with fruit (Cer + Fr)
Number of subjects: 87